APLT - Why Is Rare Disease-Focused Applied Therapeutics Stock Trading Higher Today? | Benzinga
Applied Therapeutics Inc (NASDAQ:APLT) shares are trading higher after the company, on Thursday, released interim 12-month results from the ongoing Phase 3 INSPIRE trial, in which the primary and several key secondary endpoints were achieved.
The INSPIRE Phase 3 trial evaluates the effect of once-daily (QD) oral govorestat (AT-007) in 56 patients aged 16-55 with SORD Deficiency.
SORD Deficiency is a hereditary axonal neuropathy caused by mutations in the Sorbitol Dehydrogenase gene, leading to an inability to metabolize the sugar sorbitol and resulting in the accumulation of high levels ...